In a quarterly disclosure filed on August 14, 2026, life-sciences investor Casdin Capital revealed a significant reduction in its stake in 10x Genomics (TXG). The report, which reflects holdings as of June 30, 2026, showed the firm cut its position by 53.85%, from 2.27 million shares down to 1.05 million. Due to the delayed nature of these 13F filings, the transactions occurred sometime during the second quarter.
The portfolio adjustment came before 10x Genomics reported its second-quarter earnings on August 6th. In that report, the company announced a year-over-year revenue decline and a net loss, but still beat analyst estimates and raised its full-year revenue guidance for 2026. The reported value of Casdin's remaining stake was approximately $40.26 million.